Akebia Therapeutics AKBA 深 沪
已收盘 08-15 16:00:00 美东时间
3.25
-0.040
-1.22%
华盛通- 最 高3.33
- 今 开3.29
- 成交量 370.48万股
- 最 低 3.23
- 昨 收 3.29
- 总市值 8.55亿
- 52周最高 4.0787
- 市盈率 静 --
- 换手率 1.41%
- 52周最低 1.24
- 委 比 49.73%
- 总股本 2.63亿
- 历史最高 31.00
- 量 比 0.99
- 振 幅 3.04%
- 历史最低 0.241
- 每 手 1
- 风险率 0.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akebia Therapeutics shares are trading lower following the release of its Q2 financial results.
Akebia Therapeutics shares are trading lower following the release of its Q2 fi...
08-07 21:01
Akebia Therapeutics Q2 Sales $62.472M Beat $47.637M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $62.472 million which beat the analyst consensus estimate of $47.637 million by 31.14 percent. This is a 43.13 percent increase over sales of $43.648 million
08-07 19:03
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Earnings Preview For Akebia Therapeutics
Akebia Therapeutics (NASDAQ:AKBA) is preparing to release its quarterly earning...
08-07 03:03
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Akebia Therapeutics, a biopharmaceutical company focused on improving lives affected by kidney disease, announced that CEO John P. Butler will participate in a Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 13, 2025, at 1:30 PM EDT in Boston. A webcast of the presentation will be available on Akebia’s investor website following the conference.
08-06 12:00
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
Akebia Therapeutics has initiated the VOCAL trial, a post-marketing study, to evaluate the benefits of treating patients with Vafseo three times a week. The trial, conducted at DaVita dialysis clinics, aims to assess the efficacy and safety of vadadustat compared to standard ESAs in patients with anemia due to CKD under in-center hemodialysis. Approximately 350 patients will be enrolled, with sub-studies focusing on RBC quality. The study expects...
08-04 12:00
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics will release its Q2 2025 financial results on August 7, 2025, and host a conference call at 8:00 a.m. EDT. Registration is required via the link provided, and participants should dial in 15 minutes early. A live webcast and archived version will be available on Akebia’s Investors website.
07-31 12:00
Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Akebia Therapeutics, Inc., a biopharmaceutical company focused on improving lives of kidney disease patients, announced that its Chief Commercial Officer, Nik Grund, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14 at 10:00 AM EDT. A webcast of the presentation will be available on Akebia's website following the event.
07-08 12:00
今年下半年，这9款内分泌和代谢领域新药有望获批上市
登录新浪财经APP 搜索【信披】查看更多考评等级 2025年已经过半，截至目前，国家药监局已经批准41款1类创新药上市。今年下半年，还将有一批...
07-04 10:27
1.2亿患者背后的蓝海！辉瑞/艾伯维/泽璟生物竞逐千亿白癜风赛道
（转自：摩熵医药大数据） 每年的6月25日是世界白癜风日，旨在唤起公众对白癜风疾病的关注，推动科学诊疗理念的普及，消除对患者的误解与歧视。这一纪念日的设立，与...
06-25 18:08
